Oncology Reviews

Scope & Guideline

Advancing the Frontier of Cancer Research

Introduction

Immerse yourself in the scholarly insights of Oncology Reviews with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1970-5557
PublisherFRONTIERS MEDIA SA
Support Open AccessYes
CountryItaly
TypeJournal
Convergefrom 2007 to 2024
AbbreviationONCOL REV / Oncol. Rev.
Frequency2 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND

Aims and Scopes

The journal 'Oncology Reviews' aims to provide a comprehensive platform for the dissemination of research findings, reviews, and clinical insights in the field of oncology. Its primary focus lies in enhancing the understanding of cancer biology, treatment modalities, and patient care across various cancer types.
  1. Multidisciplinary Cancer Research:
    The journal encompasses a wide array of topics related to cancer research, including molecular biology, genetics, immunology, and clinical oncology, allowing for a holistic approach to understanding cancer.
  2. Innovative Treatment Strategies:
    A consistent focus on novel therapeutic approaches, including immunotherapy, targeted therapies, and emerging treatment modalities, is evident in the journal's publications.
  3. Clinical Applications and Patient Care:
    The journal emphasizes the translation of research findings into clinical practice, addressing patient management strategies, treatment outcomes, and quality of life considerations for cancer patients.
  4. Biomarkers and Diagnostics:
    Research on biomarkers for cancer diagnosis, prognosis, and therapeutic targeting is a significant aspect of the journal, highlighting the importance of personalized medicine in oncology.
  5. Public Health and Epidemiology:
    The journal also addresses epidemiological trends and public health challenges associated with cancer, reflecting its commitment to understanding cancer in broader societal contexts.
Recent publications in 'Oncology Reviews' reveal emerging themes and trends that reflect the evolving landscape of cancer research and treatment strategies.
  1. Extracellular Vesicles and Cancer Biology:
    Research on extracellular vesicles is gaining traction, highlighting their role in tumor progression, metastasis, and as potential biomarkers for cancer diagnosis and treatment.
  2. Immunotherapy and Its Implications:
    The journal is increasingly focusing on the implications of immunotherapy, including immune checkpoint inhibitors and their effects on various cancer types, indicating a shift towards more personalized and effective treatment options.
  3. Molecular Imaging and Disease Assessment:
    Emerging studies on molecular imaging techniques for preoperative and intraoperative disease assessment signify an increasing interest in precise cancer staging and treatment planning.
  4. Connections Between Metabolic Disorders and Cancer:
    The relationship between metabolic disorders, such as diabetes, and cancer is becoming a prominent theme, suggesting an interdisciplinary approach to understanding cancer risk and management.
  5. Challenges in Cancer Treatment Delivery:
    Recent discussions on drug delivery challenges reflect a growing concern about optimizing therapeutic efficacy while minimizing side effects, indicating a trend towards more innovative treatment strategies.

Declining or Waning

In recent years, certain themes within 'Oncology Reviews' have shown a decline in prominence, reflecting shifts in research focus and funding priorities within the oncology field.
  1. Traditional Chemotherapy Approaches:
    Research focusing solely on conventional chemotherapy has decreased, as there has been a shift towards exploring personalized medicine and targeted therapies.
  2. Basic Science Without Clinical Relevance:
    Papers that emphasize basic science without clear clinical implications or applications are becoming less frequent, as there is a growing demand for research that directly impacts patient care.
  3. Single-Cancer Type Studies:
    There is a waning trend in studies that focus exclusively on single cancer types, with a move towards more integrative and comparative approaches that consider multiple types or cross-disciplinary insights.
  4. Epidemiological Studies with Limited Impact:
    Epidemiological research that does not offer actionable insights or interventions is being published less frequently, as the journal aims to prioritize studies with potential clinical applications.

Similar Journals

BULLETIN DU CANCER

Transforming cancer care with groundbreaking studies.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

ONCOLOGY REPORTS

Championing Innovative Insights in Oncology
Publisher: SPANDIDOS PUBL LTDISSN: 1021-335XFrequency: 12 issues/year

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

International Journal of Clinical Oncology

Transforming Oncology Through Innovative Insights
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Onkologie

Empowering Clinicians with Cutting-Edge Insights in Hematology.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

Oncology Research and Treatment

Innovating solutions for tomorrow's cancer challenges.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

NEOPLASIA

Transforming cancer research for a healthier tomorrow.
Publisher: ELSEVIER SCIENCE INCISSN: 1476-5586Frequency: 12 issues/year

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Transforming Cancer Knowledge into Impactful Solutions
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

ACTA ONCOLOGICA

Exploring the latest breakthroughs in cancer biology.
Publisher: Medical Journal Sweden ABISSN: 0284-186XFrequency: 12 issues/year

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

JOURNAL OF CLINICAL ONCOLOGY

Elevating the standards of cancer research and therapeutics.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

JNCI-Journal of the National Cancer Institute

Driving excellence in cancer research since 1940.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.